Trials / Completed
CompletedNCT04043975
A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
Japanese Prospective Real World Registry of Nivolumab Plus Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (ARCC) Categorized Into IMDC Intermediate/Poor Risks (J-ENCORE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 286 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the observational study is to evaluate the safety and effectiveness of combination therapy with nivolumab and ipilimumab in Japanese participants with advanced or metastatic renal cell carcinoma (aRCC) in the real-world setting in Japan.
Conditions
Timeline
- Start date
- 2019-09-19
- Primary completion
- 2024-08-23
- Completion
- 2024-08-23
- First posted
- 2019-08-02
- Last updated
- 2025-02-14
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04043975. Inclusion in this directory is not an endorsement.